Cancer incidence and mortality in Greater Poland Province in 2006 – Report

Greater Poland is a region of high cancer risk in Poland. Standardized rates for cancer incidence among man and woman are the highest in Poland. Standardized rates for cancer deaths are also very high (4th place for men and 2nd for woman).When analysing the absolute numbers of cases and deaths among men in Greater Poland for last eight years, we observe increase of cases number by 16,14% and deaths by 10,85%.Most common cancer incidence sites in Greater Poland for man are: lung, colorectum and prostate. Among woman breast, colorectum and lung.Most common cancer deaths sites in men are: lung, colorectum and stomach. Among woman breast, lung and colorectum.When analysing standardized rates for malignant tumors morbidity and mortality among men and women, we see clearly that increase of number of new cancer cases and deaths is determined first of all by ageing in Greater Poland population.Lung cancer in Greater Poland is situated in first three most common cancer sites by incidence and mortality. Region has a medium lung cancer incidence and mortality compare to other voivodships. In analyzed period (1999–2006) lung cancer incidence and mortality among men has decreased. Unfortunately the same trend is not observed among women.High breast cancer incidence is very typical for Greater Poland. Analysis of standardized rates shows that Greater Poland is on 3rd place by breast cancer incidence and on the 4th place by breast cancer mortality. The most important and at the same time the cheapest method to eliminate tumors is prophylactics and screening

Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland

The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis Area and Severity Index (PASI) before the start of the risankizumab treatment and next at the defined timepoints, i.e., 4, 16, 28, 40, 52 and 96 weeks of treatment. The percentage of patients achieving PASI90 and PASI100 responses as well as the PASI percentage decrease at the defined timepoints were calculated, and correlations with clinical characteristics and therapeutic effect were analyzed. The number of patients evaluated at the defined timepoints was: 136, 145, 100, 93, 62, and 22 at 4, 16, 28, 40, 52 and 96 weeks of treatment, respectively. At 4, 16, 28, 40, 52 and 96 weeks, the PASI90 response was achieved in 13.2%, 81.4%, 87.0%, 86.0%, 88.7% and 81.8% of patients, whereas the PASI100 response was achieved in 2.9%, 53.1%, 67.0%, 68.8%, 71.0% and 68.2% of patients, respectively. Our study revealed a significant negative correlation between a decrease in the PASI and the presence of psoriatic arthritis as well as the patient’s age and duration of psoriasis at several timepoints throughout the observation period